Carasent ASA
Research Carasent ASA (CARA) on Bullrun: valuation model: 9.7% undervalued, market cap SEK 1.56B, P/E 38.8. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCARA
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryHealth Information Services
- CurrencySEK
- Valuation signal9.7% undervalued
- Market capSEK 1.56B
- P/E38.8
- Financial periodFY2024
- RevenueSEK 275.26M
- Revenue growth12.3%
- Net income-SEK 42.26M
- Gross margin84.5%
Valuation Snapshot
Bullrun's latest valuation model marks Carasent ASA as 9.7% undervalued; latest market cap is SEK 1.56B; P/E is 38.8.
About Carasent ASA
Carasent AB (publ) provides cloud based electronic health record (EHR) systems solutions and platform services for healthcare sector in Nordics and Germany. The company offers Webdoc, Webcur, Metodika, Ad Curis, Ad Opus, and Data-AL solutions. It also provides Medrave, Vårdrummet, Ad Voca, and HPI Plustoo services, as well as an ecosystem of platform services, including solutions for patient communication and business intelligence. The company was founded in 1997 and is headquartered in Gothenburg, Sweden.
Frequently asked questions
Is Carasent ASA overvalued or undervalued?
Bullrun's valuation model currently marks Carasent ASA as 9.7% undervalued.
What is Carasent ASA's market cap?
Carasent ASA's market capitalization is SEK 1.56B.
What is Carasent ASA's P/E ratio?
Carasent ASA's price-to-earnings (P/E) ratio is 38.8.
What does Carasent ASA do?
Carasent AB (publ) provides cloud based electronic health record (EHR) systems solutions and platform services for healthcare sector in Nordics and Germany. The company offers Webdoc, Webcur, Metodika, Ad Curis, Ad Opus, and Data-AL solutions.